Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season
Open Access
- 17 April 2018
- journal article
- research article
- Published by Elsevier BV in Journal of Allergy and Clinical Immunology
- Vol. 142 (2), 678-680.e7
- https://doi.org/10.1016/j.jaci.2018.01.052
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic RhinitisJAMA, 2017
- Rhinovirus and serum IgE are associated with acute asthma exacerbation severity in childrenJournal of Allergy and Clinical Immunology, 2016
- Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb studyJournal of Allergy and Clinical Immunology, 2016
- Safety and immunogenicity of immunotherapy with Bet v 1–derived contiguous overlapping peptidesJournal of Allergy and Clinical Immunology, 2014
- Standardisation of spirometryEuropean Respiratory Journal, 2005
- Clinical and patient based evaluation of immunotherapy for grass pollen and mite allergyAllergologia et Immunopathologia, 2005
- Clinical efficacy of sublingual and subcutaneous birch pollen allergen‐specific immunotherapy: a randomized, placebo‐controlled, double‐blind, double‐dummy studyAllergy, 2003
- Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: Results of a phase I trialJournal of Allergy and Clinical Immunology, 2003
- Single-course specific immunotherapy with mixed pollen allergoids: results of a multi-centre studyAllergologia et Immunopathologia, 2003
- Development and validation of the Mini Rhinoconjunctivitis Quality of Life QuestionnaireClinical and Experimental Allergy, 2000